Stockscreener 앱 받기
17.17
1.54%
0.26
시간 외 거래:
17.18
0.010
+0.06%
전일 마감가:
$16.91
열려 있는:
$16.26
하루 거래량:
1.64M
Relative Volume:
2.46
시가총액:
$937.43M
수익:
$8.78M
순이익/손실:
$-104.70M
주가수익비율:
-7.2447
EPS:
-2.37
순현금흐름:
$-82.68M
1주 성능:
+29.58%
1개월 성능:
+42.37%
6개월 성능:
+60.77%
1년 성능:
+22.91%
1일 변동 폭
$15.50
$17.32
1주일 범위
$12.86
$17.61
52주 변동 폭
$5.35
$17.61
Stoke Therapeutics Inc Stock (STOK) Company Profile
명칭
Stoke Therapeutics Inc
전화
781-430-8200
주소
45 WIGGINS AVENUE, BEDFORD, MA
STOK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
17.17 | 926.62M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-18 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-03-26 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-07-25 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 재개 | Canaccord Genuity | Buy |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-10-24 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 개시 | Jefferies | Buy |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-11-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 개시 | UBS | Neutral |
| 2021-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-12-11 | 재확인 | Needham | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-09-29 | 개시 | Needham | Buy |
| 2019-12-18 | 개시 | Wedbush | Outperform |
| 2019-11-12 | 개시 | BTIG Research | Buy |
| 2019-10-25 | 개시 | H.C. Wainwright | Buy |
| 2019-07-15 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Credit Suisse | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
모두보기
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
Stocks With Rising Relative Price Strength: Stoke Therapeutics - MSN
Stoke Therapeutics Impresses With Strong Results For Dravet Syndrome Drug - Finimize
Stoke Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates - MSN
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Stoke Therapeutics Skyrockets 25.57%—What’s Fueling This Biotech Surge? - AInvest
Stoke Therapeutics Reports 'Impressive' Data for Severe Epilepsy Treatment, Wedbush Says - MarketScreener
Stoke Therapeutics Launches Global Phase III Trial of Zorevunersen for Dravet Syndrome. - PharmiWeb.com
Stoke Therapeutics shares rise 3.10% premarket after dosing first patient in Phase 3 trial of Zorevunersen for Dravet Syndrome. - AInvest
Stoke Therapeutics 2025 Q2 Earnings Net Income Cuts Loss by 8.6% - AInvest
Stoke Therapeutics Q2 Loss Narrows, Revenue Rises - 富途牛牛
Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic ... - Yahoo Finance
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - BioSpace
Earnings call transcript: Stoke Therapeutics beats Q2 2025 expectations - Investing.com
Stoke Therapeutics shares rise 2.73% after-hours following positive Q2 results and Phase 3 trial initiation. - AInvest
Stoke Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Stoke Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada
STOKE THERAPEUTICS Earnings Results: $STOK Reports Quarterly Earnings - Quiver Quantitative
Stoke Therapeutics Q2 2025 slides: Phase 3 Dravet trial underway, ADOA program advances - Investing.com Canada
Stoke's Dravet Syndrome Treatment Shows 3-Year Durability as Pivotal Trial Begins - Stock Titan
Can Stoke Therapeutics Inc. outperform under higher oil pricesStrong Support Zone Stocks - thegnnews.com
First patient dosed in Phase III trial of zorevunersen for Dravet syndrome - Clinical Trials Arena
Stoke Therapeutics shares fall 2.74% premarket after dosing first patient in Phase 3 EMPEROR study of zorevunersen. - AInvest
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - BioSpace
Stoke Therapeutics Earnings Preview: Analyst Expectations and Market Sentiments - AInvest
A Look Ahead: Stoke Therapeutics's Earnings Forecast - 富途牛牛
Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Ariva
First Dravet syndrome patient dosed in Phase 3 trial of zorevunersen - Investing.com Canada
Biogen, Stoke dose first patient in phase 3 Dravet syndrome trial - Investing.com Australia
Biogen, Stoke dose first patient in phase 3 Dravet syndrome trial By Investing.com - Investing.com South Africa
Biogen and Stoke Therapeutics Announce First Patient Dosed - GlobeNewswire
Institutional scanner results for Stoke Therapeutics Inc.Asset Growth Pattern and Return Summary - Newser
Building trade automation scripts for Stoke Therapeutics Inc.Free Fundamental Growth Stock Analysis - Newser
Multi asset correlation models including Stoke Therapeutics Inc.Free Trend Following Strategy With Stop Loss - Newser
Can momentum traders help lift Stoke Therapeutics Inc.Free Wealth Building Stock Market Ideas - Newser
Will Stoke Therapeutics Inc. bounce back from current supportLow Drawdown Stock Screener with Analysis - Newser
Stoke Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayEquity Forecast with Predictive AI Screener - Newser
Stoke Therapeutics Inc. Outperforms Peers on Volume MetricsAccurate Buy Point for Momentum Stocks Detected - beatles.ru
Stoke Therapeutics STOK 2025Q2 Earnings Preview Upside Potential on Innovative Fluorescence Applications - AInvest
Stoke Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Stoke Therapeutics to Host Q2 2025 Business and Financial Update Webcast and Conference Call. - AInvest
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates - The Globe and Mail
Stoke Therapeutics Earnings Call to Reveal Latest Progress on Revolutionary Dravet Syndrome Treatment - Stock Titan
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - BioSpace
Published on: 2025-08-05 00:18:53 - beatles.ru
Combining machine learning predictions for Stoke Therapeutics Inc.Predictive Short-Term Market Reversal Alerts - Newser
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Trendline Breach Raises Concern for Stoke Therapeutics Inc. InvestorsVerified Signal From Chart Patterns Detected - metal.it
Should I hold or sell Stoke Therapeutics Inc. stock in 2025Maximize returns with strategic portfolio planning - Jammu Links News
Is Stoke Therapeutics Inc. a growth stock or a value stockRemarkable growth - Jammu Links News
Stoke Therapeutics Inc (STOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
1.56%
자본화:
|
볼륨(24시간):